Switching Anti-Vascular Endothelial Growth Factors in Refractory Neovascular Age-Related Macular Degeneration
Author:
Publisher
SLACK, Inc.
Subject
Ophthalmology,Surgery
Reference37 articles.
1. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;CATT Research Group;N Engl J Med,2011
2. Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration;Stoller GL;JAMA Ophthalmol,2016
3. Characteristics and predictors of early and delayed responders to ranibizumab treatment in neovascular age-related macular degeneration: A retrospective analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials;Gale R;Ophthalmologica,2016
4. Switching treatment for neovascular age-related macular degeneration from bevacizumab to ranibizumab: Who is likely to benefit from the switch?;Moisseiev E;Retina,2015
5. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD;Ehlken C;Eye (Lond),2014
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice;Clinical Ophthalmology;2024-06
2. Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand;Journal of Ocular Pharmacology and Therapeutics;2023-12-20
3. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment;European Journal of Ophthalmology;2023-07-18
4. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities;Progress in Retinal and Eye Research;2021-05
5. Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting;Graefe's Archive for Clinical and Experimental Ophthalmology;2021-01-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3